Cytokine Release Syndrome Following Blinatumomab Therapy
Pius Ojemolon, Sunaina Kalidindi, Taylor A Ahlborn, Osaigbokan Aihie, Moyosoluwa I Awoyomi
Abstract
New therapeutic solutions have emerged in the last few decades with the growth and expansion of the field of cancer research. Amongst these new agents, immunotherapy has been prominent, particularly regarding the treatment of hematologic malignancies. One of the most worrisome complications of immunotherapy is cytokine release syndrome (CRS), which represents a supraphysiologic response resulting in excessive release of cytokines and a wide range of systemic manifestations. In this case report, we present a case of cytokine release syndrome following blinatumomab therapy despite premedication with dexamethasone.
Topics & Concepts
MedicineBlinatumomabCytokine release syndromeCytokineImmunotherapyPremedicationDexamethasoneImmunologyOncologyCancerInternal medicineAnesthesiaImmune systemChimeric antigen receptorCD19CAR-T cell therapy researchLymphoma Diagnosis and TreatmentCNS Lymphoma Diagnosis and Treatment